An interventional study of Driving Pressure-Guided Ventilator Optimization in Acute Kidney Failure, Mechanical Ventilation Strategies and Right Ventricular (RV) Dysfunction, sponsored by Nardin Aymn Boshra. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Nardin Aymn Boshra · Not applicable, Interventional, and Supportive care
Among 64 studies in Acute Kidney Injury with a site in Egypt — 21 open to participants now, 22 under way, 1 of them phase 3. Acute Kidney Injury · Egypt.
Among the 64 studies in Acute Kidney Injury with a site in Egypt, this one is the 9th largest by planned enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2026, is one of 18 with no phase, reaches primary completion later than 18 of the 21 other live ones, and was the 62nd registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 395 are open to participants now.
Browse Acute Kidney Injury studies →21 of the 64 studies in Acute Kidney Injury with a site in Egypt are open now. Recruiting first, the newest first:
Beni-Suef University · Sites in Egypt
Ages 18+
Beni-Suef University · Sites in Egypt
Ages 18+
Assiut University · Sites in Egypt
Ages 18–70
Ain Shams University · Sites in Egypt
Ages 30–65
Ain Shams University · Sites in Egypt
Ages 18–65
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 230 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 36 (16%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 100 across 817 interventional studies indexed under Acute Kidney Injury.
Median enrollment 90 across the 27 interventional studies, 100 across the 37 observational. Of the 30 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 64 has an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Nardin Aymn Boshra as lead sponsor.
Nardin Aymn Boshra has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
7 of the studies in Acute Kidney Injury with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06408597Nazmy Edward SeifMannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | 2026-11 |
| NCT07873372Ain Shams UniversityRutin and Ascorbic Acid for Prevention of Vancomycin-Induced Nephrotoxicity in Adult Patients" - a Clinical Trial Protocol Evaluating Whether Combined Rutin/Vitamin C Supplementation Reduces Kidney Toxicity From Vancomycin, Compared to Vitamin C Alone and Control. | 2026-12-01 |
| NCT06753409Assiut UniversityProcessed Electroencephalography-guided General Anesthesia and Outcomes in Major Abdominal Surgery | 2026-12-01 |
| NCT07636083Sohag UniversityAcute Kidney Injury in Upper GI Bleeding Patients | 2027-01-15 |
| NCT07627880Beni-Suef UniversityInitial Drainage Method and Flexible Ureteroscopy Outcomes in Calculous Anuria | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Acute Kidney Injury with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates the effect of driving pressure optimization on right ventricular-pulmonary artery (RV-PA) coupling, assessed by TAPSE/PASP ratio, and its association with acute kidney injury (AKI) progression in mechanically ventilated critically ill patients.
The tricuspid annular plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP) ratio is a validated, non-invasive bedside surrogate for RV-PA coupling, shown to correlate closely with invasively measured pressure-volume loop indices of RV-arterial coupling and to carry independent prognostic value in heart failure and pulmonary hypertension populations. More recently, TAPSE-based coupling indices have also demonstrated prognostic relevance in general critically ill populations, supporting their applicability outside the setting of chronic cardiopulmonary disease.
Separately, driving pressure (the difference between plateau pressure and PEEP) has emerged as a key determinant of ventilator-induced lung injury and mortality in ARDS, independent of tidal volume or PEEP in isolation, building on earlier evidence that lower tidal volume ventilation strategies improve outcomes in acute lung injury and ARDS.
This study will investigate whether a simple standardized lung-protective ventilation strategy aimed at optimizing ventilator driving pressure can improve RV-PA coupling, assessed by TAPSE/PASP ratio, and reduce AKI progression in mechanically ventilated critically ill patients.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients ventilated using a standardized protocol targeting driving pressure optimization (ΔP ≤15 cmH2O\]) through adjustment of tidal volume and/or PEEP, in addition to standard critical care management.
Other: Driving Pressure-Guided Ventilator Optimization
Patients ventilated according to standard ventilation practice
A ventilator management strategy in which tidal volume and/or PEEP are titrated to minimize driving pressure (plateau pressure - PEEP) to a pre-specified target, aiming to improve RV-PA coupling and reduce AKI progression.
TAPSE/PASP ratio (RV-PA coupling)
Baseline transthoracic echocardiography will be performed before initiation of the intervention whenever feasible, recording: TAPSE, PASP (estimated from tricuspid regurgitant jet velocity and estimated right atrial pressure), MAPSE (LV longitudinal function parameter), Inferior vena cava (IVC) collapsibility index. Repeat echocardiography will be performed approximately 48-72 hours after initiation of the intervention, using the same measurements.
Time frame: On admission and 48-72 hours after
Acute kidney injury progression
Serum creatinine and urine output will be recorded at baseline and daily for the first 7 days of mechanical ventilation, or until ICU discharge/death if earlier. AKI will be staged according to KDIGO criteria with primary renal endpoint: AKI progression, defined as an increase in KDIGO stage during the 7-day observation period. New AKI and worsening of established AKI may also be described separately.
Time frame: 1 week
Plan to share: No
Start is estimated for Oct 2026; primary completion for Aug 2027, 10 months later.
Of 249 non-industry interventional studies with no phase under Acute Kidney Injury, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 10 months is below that.
Counting every sponsor, half of 267 studies reached it within 26 months; a quarter within 12 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.